CryoPort (CYRX) vs Omeros (OMER)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
CryoPort (CYRX) has outperformed Omeros (OMER) over the past year, gaining 117.0% versus a gain of 48.9%. Over five years, OMER leads with a +77.8% price change compared with -71.4% for CYRX. Omeros is the larger company by market cap ($983.7 million vs $964.9 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CYRX | OMER |
|---|---|---|
| Share price | $19.05 | $13.21 |
| Market cap | $964.87M | $983.66M |
| 1-day change | -2.56% | -5.71% |
| YTD return | +98.44% | -23.11% |
| 1-year return | +116.97% | +48.93% |
| 5-year return | -71.38% | +77.79% |
| P/E ratio (TTM) | — | 15.92 |
| Forward P/E | — | 11.95 |
| EPS (TTM) | $-0.90 | $0.83 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $176.18M | — |
| Revenue growth (YoY) | +12.38% | — |
| Net income (latest FY) | $78.30M | $-3.35M |
| Gross margin | 47.14% | — |
| Operating margin | -20.89% | — |
| Net margin | 44.44% | — |
| 52-week high | $21.78 | $21.24 |
| 52-week low | $7.61 | $6.70 |
| Distance from 52-week high | -12.53% | -37.81% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +17.22% | +108.18% |
| Average volume | 843.80K | 1.36M |
| Shares outstanding | 50.65M | 74.46M |
| Employees | 684 | 175 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CYRX has outperformed OMER by 68.0 percentage points over the past year.
About CryoPort
CYRX stock →Cryoport, Inc. provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and reproductive medicine markets worldwide.
Health Care · Biotechnology: Pharmaceutical Preparations · 684 employees
About Omeros
OMER stock →Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases. The company's lead products candidate is the Narsoplimab (OMS721/MASP-2) for the treatment of hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); and in Phase II clinical trial to treat COVID-19 and acute respiratory distress syndrome.
Health Care · Biotechnology: Pharmaceutical Preparations · 175 employees
CYRX vs OMER FAQ
Which is bigger, CryoPort or Omeros?
Omeros (OMER) is larger, with a market capitalization of $983.66M compared with $964.87M for CryoPort (CYRX).
Which stock has performed better over the past year, CYRX or OMER?
CYRX returned +116.97% over the past 12 months, compared with +48.93% for OMER (price return, excluding dividends). Past performance does not predict future results.
Are CryoPort and Omeros in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.